TY - JOUR
T1 - Medication Possession Ratio Predicts Antiretroviral Regimens Persistence in Peru
AU - Salinas, Jorge L.
AU - Alave, Jorge L.
AU - Westfall, Andrew O.
AU - Paz, Jorge
AU - Moran, Fiorella
AU - Carbajal-Gonzalez, Danny
AU - Callacondo, David
AU - Avalos, Odalie
AU - Rodriguez, Martin
AU - Gotuzzo, Eduardo
AU - Echevarria, Juan
AU - Willig, James H.
N1 - Funding Information:
The authors have the following interests. A.O.W. has consulted for Definicare. J.H.W. has received research support from Bristol Myers Squibb, Pfizer, Tibotec, and Definicare and has received consulting fees from Bristol Myers Squibb and Gilead. All other authors report no potential conflicts. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - Objectives:In developing nations, the use of operational parameters (OPs) in the prediction of clinical care represents a missed opportunity to enhance the care process. We modeled the impact of multiple measurements of antiretroviral treatment (ART) adherence on antiretroviral treatment outcomes in Peru.Design And Methods:Retrospective cohort study including ART naïve, non-pregnant, adults initiating therapy at Hospital Nacional Cayetano Heredia, Lima-Peru (2006-2010). Three OPs were defined: 1) Medication possession ratio (MPR): days with antiretrovirals dispensed/days on first-line therapy; 2) Laboratory monitory constancy (LMC): proportion of 6 months intervals with ≥1 viral load or CD4 reported; 3) Clinic visit constancy (CVC): proportion of 6 months intervals with ≥1 clinic visit.Three multi-variable Cox proportional hazard (PH) models (one per OP) were fit for (1) time of first-line ART persistence and (2) time to second-line virologic failure. All models were adjusted for socio-demographic, clinical and laboratory variables.Results:856 patients were included in first-line persistence analyses, median age was 35.6 years [29.4-42.9] and most were male (624; 73%). In multivariable PH models, MPR (per 10% increase HR=0.66; 95%CI=0.61-0.71) and LMC (per 10% increase 0.83; 0.71-0.96) were associated with prolonged time on first-line therapies.Among 79 individuals included in time to second-line virologic failure analyses, MPR was the only OP independently associated with prolonged time to second-line virologic failure (per 10% increase 0.88; 0.77-0.99).Conclusions:The capture and utilization of program level parameters such as MPR can provide valuable insight into patient-level treatment outcomes.
AB - Objectives:In developing nations, the use of operational parameters (OPs) in the prediction of clinical care represents a missed opportunity to enhance the care process. We modeled the impact of multiple measurements of antiretroviral treatment (ART) adherence on antiretroviral treatment outcomes in Peru.Design And Methods:Retrospective cohort study including ART naïve, non-pregnant, adults initiating therapy at Hospital Nacional Cayetano Heredia, Lima-Peru (2006-2010). Three OPs were defined: 1) Medication possession ratio (MPR): days with antiretrovirals dispensed/days on first-line therapy; 2) Laboratory monitory constancy (LMC): proportion of 6 months intervals with ≥1 viral load or CD4 reported; 3) Clinic visit constancy (CVC): proportion of 6 months intervals with ≥1 clinic visit.Three multi-variable Cox proportional hazard (PH) models (one per OP) were fit for (1) time of first-line ART persistence and (2) time to second-line virologic failure. All models were adjusted for socio-demographic, clinical and laboratory variables.Results:856 patients were included in first-line persistence analyses, median age was 35.6 years [29.4-42.9] and most were male (624; 73%). In multivariable PH models, MPR (per 10% increase HR=0.66; 95%CI=0.61-0.71) and LMC (per 10% increase 0.83; 0.71-0.96) were associated with prolonged time on first-line therapies.Among 79 individuals included in time to second-line virologic failure analyses, MPR was the only OP independently associated with prolonged time to second-line virologic failure (per 10% increase 0.88; 0.77-0.99).Conclusions:The capture and utilization of program level parameters such as MPR can provide valuable insight into patient-level treatment outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84884885237&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0076323
DO - 10.1371/journal.pone.0076323
M3 - Article
C2 - 24098475
AN - SCOPUS:84884885237
SN - 1932-6203
VL - 8
JO - PLoS ONE
JF - PLoS ONE
IS - 10
M1 - e76323
ER -